Investors Buy High Volume of Call Options on Marinus Pharmaceuticals (NASDAQ:MRNS)

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) saw unusually large options trading activity on Monday. Stock investors purchased 7,569 call options on the stock. This is an increase of 1,571% compared to the average volume of 453 call options.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on MRNS shares. Royal Bank of Canada decreased their target price on shares of Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating for the company in a research note on Friday, October 25th. Truist Financial cut Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 24th. HC Wainwright reissued a “neutral” rating and issued a $2.00 target price on shares of Marinus Pharmaceuticals in a report on Thursday, November 14th. TD Cowen reaffirmed a “hold” rating on shares of Marinus Pharmaceuticals in a report on Friday, October 25th. Finally, StockNews.com started coverage on shares of Marinus Pharmaceuticals in a research note on Saturday. They issued a “hold” rating on the stock. Nine research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $4.79.

Institutional Investors Weigh In On Marinus Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of MRNS. Point72 DIFC Ltd acquired a new position in Marinus Pharmaceuticals during the second quarter worth $28,000. AQR Capital Management LLC boosted its position in shares of Marinus Pharmaceuticals by 70.3% in the 2nd quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock worth $37,000 after buying an additional 12,934 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Marinus Pharmaceuticals in the 2nd quarter valued at about $64,000. World Investment Advisors LLC purchased a new position in Marinus Pharmaceuticals during the 3rd quarter valued at about $104,000. Finally, Hussman Strategic Advisors Inc. raised its position in Marinus Pharmaceuticals by 14.3% during the second quarter. Hussman Strategic Advisors Inc. now owns 84,000 shares of the biopharmaceutical company’s stock worth $98,000 after acquiring an additional 10,500 shares during the last quarter. Institutional investors and hedge funds own 98.80% of the company’s stock.

Marinus Pharmaceuticals Trading Up 41.7 %

MRNS stock opened at $0.53 on Tuesday. Marinus Pharmaceuticals has a 52 week low of $0.22 and a 52 week high of $11.26. The company has a market cap of $29.03 million, a P/E ratio of -0.21 and a beta of 1.25. The company’s 50-day moving average price is $0.37 and its 200 day moving average price is $1.07.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.